For Q1 FY2026 ended March 31, 2026, Xenon Pharmaceuticals reported zero revenue, a net loss of $102.3 million (57.3% wider YoY), and an operating loss of $112.3 million (54.4% wider YoY). Diluted EPS was -$1.17, compared to -$0.83 in the prior year. The company held $545.9 million in cash and $1.34 billion in equity, with no long-term debt.
•Revenue was $0, down 100% YoY.
•Net loss widened to $102.3 million from $65.0 million.
•Diluted EPS was -$1.17, a 41% decline YoY.
•Cash and equivalents stood at $545.9 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company provides the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders.
Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy Including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Additionally, it's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain.
The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Incorporated in 1996, Xenon Pharmaceuticals is headquartered in Burnaby, Canada.
Xenon Pharmaceuticals Inc. is a neuroscience-focused biopharmaceutical company that discovers, develops, and delivers therapeutics for neurological and psychiatric disorders. Its lead product candidate is Azetukalner, a novel Kv7 potassium channel opener currently in Phase 3 clinical development for epilepsy (focal onset seizures and primary generalized tonic-clonic seizures) and neuropsychiatric conditions like major depressive disorder and bipolar depression. The company also has early-stage programs: XEN1701, a sodium channel-targeting candidate, and XEN1120, a Kv7 potassium channel opener, both in Phase 1 trials for pain. Additionally, Xenon has a collaboration with Neurocrine Biosciences for NBI-921355, a Nav1.2/1.6 sodium channel inhibitor in Phase 1 for certain epilepsies.
Where is Xenon Pharmaceuticals (XENE) listed and in which currency?
Xenon Pharmaceuticals Inc. is listed on the Nasdaq Global Market (NasdaqGM) under the ticker symbol XENE. Its shares trade in US Dollars (USD), as the exchange is based in the United States. The company is headquartered in Burnaby, Canada, but its stock is traded on a US exchange, making it accessible to international investors. The listing on NasdaqGM provides liquidity and visibility within the US capital markets.
What sector and industry does Xenon Pharmaceuticals (XENE) operate in?
Xenon Pharmaceuticals operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on researching and developing novel therapies for neurological and psychiatric disorders. Its work involves advanced science around ion channels, particularly potassium and sodium channels, to create treatments for conditions like epilepsy, depression, and pain. The biotechnology industry is characterized by high research and development costs, long development timelines, and significant regulatory oversight, which Xenon navigates as it advances its pipeline.
Where is Xenon Pharmaceuticals (XENE) headquartered and what markets does it serve?
Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada, and was incorporated in 1996. While based in Canada, the company primarily serves the US market, as indicated by its listing on the NasdaqGM and its clinical trials conducted in the US. Its pipeline targets neurological and psychiatric disorders that affect patients globally, but its current focus is on advancing therapies for epilepsy, depression, bipolar disorder, and pain. The company collaborates with partners like Neurocrine Biosciences, which is US-based, to develop treatments for epilepsy.
What is the business model of Xenon Pharmaceuticals (XENE) and how does it generate revenue?
Xenon Pharmaceuticals is a development-stage biopharmaceutical company with no approved products yet, so it does not generate revenue from product sales. Its business model centers on research and development of novel therapies for neurological and psychiatric disorders. The company generates revenue through collaboration agreements, such as its license and collaboration with Neurocrine Biosciences for NBI-921355. Under this deal, Xenon likely receives upfront payments, milestone payments, and potential royalties if the product is commercialized. The company's primary focus is advancing its own pipeline, including Azetukalner (Phase 3) and early-stage candidates XEN1701 and XEN1120, which may lead to future partnerships or commercialization.